scholarly journals Immunotherapy for pediatric brain tumors: past and present

2019 ◽  
Vol 21 (10) ◽  
pp. 1226-1238 ◽  
Author(s):  
Jessica B Foster ◽  
Peter J Madsen ◽  
Meenakshi Hegde ◽  
Nabil Ahmed ◽  
Kristina A Cole ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Pediatric Brain Tumors ◽  
Adoptive T Cell Therapy ◽  
Active Immunotherapy ◽  
T Cell Therapy ◽  
The Past ◽  
Formidable Challenge ◽  
Recent Developments ◽  
Pediatric Brain

AbstractThe field of cancer immunotherapy has progressed at an accelerated rate over the past decade. Pediatric brain tumors thus far have presented a formidable challenge for immunotherapy development, given their typically low mutational burden, location behind the blood–brain barrier in a unique tumor microenvironment, and intratumoral heterogeneity. Despite these challenges, recent developments in the field have resulted in exciting preclinical evidence for various immunotherapies and multiple clinical trials. This work reviews the history and advances in active immunotherapy, checkpoint blockade, and adoptive T-cell therapy for pediatric brain tumors, including ongoing clinical trials.

Clinical Trials in Pediatric Brain Tumors; Radiotherapy

2012 ◽  
pp. 183-197 ◽  
Author(s):  
Anna Skowronska-Gardas ◽  
Marzanna Chojnacka ◽  
Katarzyna Pedziwiatr
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Pediatric Brain Tumors ◽  
Pediatric Brain

scholarly journals Clinical trials using molecular stratification of pediatric brain tumors

2020 ◽  
Vol 9 (2) ◽  
pp. 144-156
Author(s):  
Samuel Z. Hanz ◽  
Oluwaseyi Adeuyan ◽  
Grace Lieberman ◽  
Tammy Hennika
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Pediatric Brain Tumors ◽  
Molecular Stratification ◽  
Pediatric Brain

scholarly journals New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy

2021 ◽  
Vol 22 (5) ◽  
pp. 2404
Author(s):  
Wan-Tai Wu ◽  
Wen-Ying Lin ◽  
Yi-Wei Chen ◽  
Chun-Fu Lin ◽  
Hsin-Hui Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Brain Tumors ◽  
Cell Therapy ◽  
Pediatric Brain Tumors ◽  
T Cell Therapy ◽  
New Era ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Pediatric Brain

Immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, cancer vaccines, and dendritic cell therapy, has been incorporated as a fifth modality of modern cancer care, along with surgery, radiation, chemotherapy, and target therapy. Among them, CAR T-cell therapy emerges as one of the most promising treatments. In 2017, the first two CAR T-cell drugs, tisagenlecleucel and axicabtagene ciloleucel for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), respectively, were approved by the Food and Drug Administration (FDA). In addition to the successful applications to hematological malignancies, CAR T-cell therapy has been investigated to potentially treat solid tumors, including pediatric brain tumor, which serves as the leading cause of cancer-associated death for children and adolescents. However, the employment of CAR T-cell therapy in pediatric brain tumors still faces multiple challenges, such as CAR T-cell transportation and expansion through the blood–brain barrier, and identification of the specific target antigen on the tumor surface and immunosuppressive tumor microenvironment. Nevertheless, encouraging outcomes in both clinical and preclinical trials are coming to light. In this article, we outline the current propitious progress and discuss the obstacles needed to be overcome in order to unveil a new era of treatment in pediatric brain tumors.

Sign in / Sign up

Export Citation Format

Share Document